Stockscreener 앱 받기
2.69
6.60%
-0.19
전일 마감가:
$2.88
열려 있는:
$2.91
하루 거래량:
26,944
Relative Volume:
0.11
시가총액:
$1.76M
수익:
-
순이익/손실:
$-13.03M
주가수익비율:
-0.0217
EPS:
-124.0371
순현금흐름:
$-6.53M
1주 성능:
-7.24%
1개월 성능:
-38.44%
6개월 성능:
-65.88%
1년 성능:
+0.00%
1일 변동 폭
$2.69
$2.91
1주일 범위
$2.69
$3.29
52주 변동 폭
$2.69
$16.92
Decoy Therapeutics Inc Stock (DCOY) Company Profile
명칭
Decoy Therapeutics Inc
전화
346-772-0346
주소
2450 HOLCOMBE BLVD, HOUSTON
Compare DCOY vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DCOY
Decoy Therapeutics Inc
|
2.69 | 2.15M | 0 | -13.03M | -6.53M | -124.04 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Decoy Therapeutics Inc Stock (DCOY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-23 | 개시 | Ladenburg Thalmann | Buy |
| 2020-04-27 | 개시 | Ladenburg Thalmann | Buy |
Decoy Therapeutics Inc 주식(DCOY)의 최신 뉴스
ARMISTICE CAPITAL, LLC Acquires Shares of Decoy Therapeutics Inc (DCOY) - GuruFocus
Decoy (DCOY) Latest Quarter: The Available Earnings Metric Delivers a Beat on the Day; After Earnings: Shares Rise 0.29% in the Latest SessionRevenue Guidance Range - vinanet.vn
Decoy (DCOY) Trading Levels Update: Adds 1.14% to Close at $3.56 for the Current Session; Chart Reference - vinanet.vn
DCOY Q3 2024 Earnings: Narrower Loss of -136.8 per Share Delivers Positive SurpriseCash Flow Report - vinanet.vn
Decoy Therapeutics (DCOY) Advances 1.42% to $3.58, Holding Above SupportCTA Positioning - Vinanet
Armistice Capital (DCOY) discloses 65,503-share, 9.99% holding in Decoy Therapeutics - Stock Titan
DCOY Q2'26 Earnings: EPS estimate is (2.88) USD - TradingView
Decoy Therapeutics: Q2 Earnings Snapshot - Barchart.com
Decoy Therapeutics: Q2 Earnings Snapshot | Associated Press | syndication news - Enidnews.com
Decoy Therapeutics Inc. Q2 2026: Revenue $0.23M, Net loss $(2.37M), EPS $(4.46) — 10-Q Summary - TradingView
Decoy Therapeutics (DCOY) posts wider Q2 loss, flags going-concern and Nasdaq risks - Stock Titan
Decoy Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
DCOY Q3 2024 Earnings: Loss Narrows Sharply, Delivering 68.95% Positive EPS SurpriseGuidance Accuracy Score - vinanet.vn
Decoy Therapeutics Expands Intellectual Property Portfolio Covering Designable Multi-Antivirals and the IMP³ACT™ Platform - Morningstar
Decoy Therapeutics expands IP portfolio to 19 applications By Investing.com - Investing.com Nigeria
Decoy Therapeutics expands IP portfolio to 19 applications - Investing.com
Decoy's antiviral applications span 7 jurisdictions, with 19 pending - Stock Titan
Decoy Therapeutics (DCOY) Holds Firm Above $4 as Traders Eye Key Resistance at $4.32Wyckoff Accumulation - Vinanet
DCOY Q3 2024 Earnings: Loss Narrows Sharply, Beating Estimates by 68.95%Earnings Trend Analysis - vinanet.vn
DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss of -136.8 per Share Highlights Cost DisciplineROA Comparison - vinanet.vn
DCOY Q3 2024 Earnings: Loss Narrower Than Expected as Cost Controls Take EffectShort-Term Outlook - Vinanet
Decoy Therapeutics (DCOY) Advances Research on D-MAV Candidates for Filoviruses - GuruFocus
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAVtm Platform into High Consequence Global Health Threats - Lelezard
Decoy Therapeutics’ D-MAV platform shows inhibition of Ebola Zaire virus - TipRanks
Decoy Therapeutics Announces Breakthrough In Vitro Activity Against Ebola Zaire, Expanding D-MAV™ Platform into High Consequence Global Health Threats - Morningstar
Decoy candidate shows activity against Ebola and Lassa in tests - Stock Titan
Decoy Therapeutics (DCOY) Plunges 22%: Key Support Level in FocusDividend Arbitrage - vinanet.vn
Decoy Therapeutics Inc. Revenue Breakdown – MUN:FP11 - TradingView
DCOY Q3 2024 Earnings: Narrower Loss Surprises; Pre-Revenue Stage Remains FocusEarnings Acceleration Picks - vinanet.vn
Decoy Therapeutics (DCOY) pursues warrant approvals and cuts authorized shares - Stock Titan
Decoy Therapeutics Inc. (NASDAQ: DCOY) Share Price, DCOY Stock News, DCOY Share Price & Updates - Kalkine
Decoy Therapeutics Inc. Revenue Breakdown – FWB:FP11 - TradingView
Decoy Therapeutics (DCOY) Rallies 1.42% as Shares Test Key Resistance at $5.24Fear Greed Extreme - vinanet.vn
Decoy Therapeutics Inc. SEC Filing (Jul 20, 2026) - Stock Titan
$5.86 | Decoy Therapeutics Inc. Common Stock (DCOY) Stock Price Today - Binance
DCOY Q3 2024 Earnings: Narrower-Than-Expected Loss Fails to Lift Sentiment as Stock Slides 10%Revenue Inflection Point - vinanet.vn
DCOY Q3 2024 Earnings: Smaller-than-Expected Loss Signals Cost Discipline Amid Clinical ProgressSaaS Earnings Trends - dars.gov.et
Enterprise value to EBITDA forward of Decoy Therapeutics Inc. – FWB:FP11 - TradingView
Enterprise value to EBIT forward of Decoy Therapeutics Inc. – FWB:FP11 - TradingView
Decoy Therapeutics Inc. (DCOY) Files 8-K: Key Company Information, Address, and Nasdaq Listing Details (July 2026) - Minichart
Decoy Therapeutics (DCOY) Jumps 7.5%: Support Holds While Resistance LoomsStrong Buy Stocks - dars.gov.et
Decoy Therapeutics (Nasdaq: DCOY) details 2026 annual meeting votes - Stock Titan
Decoy Therapeutics Inc. Elects Patricia Gauthier as Class II Director - marketscreener.com
Decoy Therapeutics elects Patricia Gauthier to board By Investing.com - Investing.com Nigeria
Decoy Therapeutics elects Patricia Gauthier to board - Investing.com
Decoy Therapeutics Appoints New Board Member - Intellectia AI
Press Release: Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors - Moomoo
Decoy Therapeutics Stockholders Elect Patricia Gauthier to Board of Directors - Nasdaq
DCOY Q3 2024 Earnings: Narrower‑than‑Expected Loss Surprises Markets; Stock Slips ModestlyEarnings Outlook Update - vinanet.vn
Decoy Therapeutics Company Profile & Introduction - Moomoo
Price to earnings forward of Decoy Therapeutics Inc. – NASDAQ:DCOY - TradingView
Decoy Therapeutics Inc (DCOY) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Decoy Therapeutics Inc 주식 (DCOY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| HANISH ARNOLD C | Director |
Dec 30 '25 |
Sale |
0.64 |
12 |
8 |
0 |
| HANISH ARNOLD C | Director |
Nov 20 '25 |
Buy |
0.75 |
5,000 |
3,740 |
5,015 |
| Rosenblum Mark J | Exec VP Finance, CFO |
Nov 20 '25 |
Buy |
0.80 |
20,000 |
16,000 |
20,177 |
0.86%
0.31%
자본화:
|
볼륨(24시간):